View Older Stories

Apr 27, 2026 02:50PM Intellia Therapeutics (NTLA) PT Raised to $30 at Chardan

Apr 27, 2026 01:10PM Intellia Therapeutics (NTLA) PT Raised to $35 at Leerink Partners

Apr 27, 2026 11:34AM Intellia Therapeutics (NTLA) PT Raised to $15 at Morgan Stanley

Apr 27, 2026 10:48AM TD Cowen on Intellia Therapeutics (NTLA): 'We see the Ph. III results as solid'

Apr 27, 2026 10:10AM Intellia Therapeutics (NTLA) PT Raised to $20 at BofA Securities

Apr 27, 2026 07:03AM Intellia begins rolling FDA submission for gene editing therapy

Mar 4, 2026 06:01AM Jones Trading Upgrades Intellia Therapeutics (NTLA) to Buy

Mar 3, 2026 09:54AM Brookline Capital Markets Reiterates Buy Rating on Intellia Therapeutics (NTLA), PT $106

Mar 3, 2026 07:30AM Intellia presents longer-term data for hereditary angioedema treatment

Mar 3, 2026 04:56AM Intellia Therapeutics (NTLA) PT Raised to $28 at Citizens After Very Positive FDA Action

Mar 2, 2026 03:25PM Baird Reiterates Neutral Rating on Intellia Therapeutics (NTLA)

Mar 2, 2026 02:48PM Intellia Therapeutics (NTLA) PT Raised to $15 at RBC Capital

Mar 2, 2026 02:18PM Intellia Therapeutics (NTLA) PT Raised to $27 at Chardan

Mar 2, 2026 02:04PM Oppenheimer on Intellia Therapeutics (NTLA): 'We view the resolution of the clinical trial holds for nex-z as relatively fast and favorable'

Mar 2, 2026 12:28PM Goldman on Intellia Therapeutics (NTLA): 'While shares are trading higher after the news, safety could remain an overhang given the specific risk factors'

Mar 2, 2026 12:05PM William Blair Upgrades Intellia Therapeutics (NTLA) to Outperform

Mar 2, 2026 10:25AM Intellia Therapeutics (NTLA) PT Raised to $19 at BofA Securities

Mar 2, 2026 10:04AM Intellia Therapeutics (NTLA) PT Raised to $16 at Evercore ISI

Feb 26, 2026 01:31PM Goldman: ' the inability to fully screen at-risk patients could be a factor in the competitive dynamics in ATTR'

Feb 26, 2026 01:28PM TD Cowen Reiterates Buy Rating on Intellia Therapeutics (NTLA)

Feb 26, 2026 07:35AM Intellia Therapeutics (NTLA) Tops Q4 EPS by 13c

Jan 28, 2026 06:39AM Intellia Therapeutics (NTLA) PT Raised to $25 at H.C. Wainwright

Jan 27, 2026 11:29AM Intellia Therapeutics (NTLA) PT Raised to $7 at Baird

Dec 19, 2025 09:06AM TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'

Nov 11, 2025 04:31PM Wolfe Research Downgrades Intellia Therapeutics (NTLA) to Peerperform

Nov 11, 2025 07:17AM Jones Trading Downgrades Intellia Therapeutics (NTLA) to Hold

Nov 11, 2025 03:20AM Evercore ISI Downgrades Intellia Therapeutics (NTLA) to In Line

Nov 7, 2025 08:56AM Intellia Therapeutics (NTLA) PT Lowered to $9 at RBC Capital

Nov 7, 2025 04:48AM Baird Reiterates Neutral Rating on Intellia Therapeutics (NTLA)

Nov 7, 2025 03:50AM JPMorgan Downgrades Intellia Therapeutics (NTLA) to Underweight

Nov 6, 2025 04:29PM Intellia Therapeutics (NTLA) Tops Q3 EPS by 9c

Oct 31, 2025 09:54AM FDA Clears Way for Faster Personalized Gene Editing Treatments

Oct 31, 2025 07:27AM BofA Securities Downgrades Intellia Therapeutics (NTLA) to Neutral, 'FDA pause lowers contribution from key value driver'

Oct 30, 2025 04:55AM Intellia Therapeutics (NTLA) PT Lowered to $9 at Baird

Oct 29, 2025 04:24PM FDA places clinical hold on Intellia's MAGNITUDE trials for nex-z

Oct 28, 2025 06:41AM Intellia Therapeutics (NTLA) PT Lowered to $25 at H.C. Wainwright

Oct 28, 2025 06:26AM Canaccord Genuity Reiterates Buy Rating on Intellia Therapeutics (NTLA)

Oct 28, 2025 04:23AM Intellia Therapeutics (NTLA) PT Lowered to $29 at Citizens on Nex-Z (ATTR) Risk

Oct 28, 2025 03:30AM William Blair Downgrades Intellia Therapeutics (NTLA) to Market Perform

Oct 28, 2025 03:30AM Bernstein SocGen Group Downgrades Intellia Therapeutics (NTLA) to Market Perform

Oct 28, 2025 03:29AM RBC Capital Downgrades Intellia Therapeutics (NTLA) to Sector Perform

Oct 27, 2025 02:17PM Intellia Therapeutics (NTLA) PT Lowered to $33 at Oppenheimer

Oct 27, 2025 10:23AM Intellia Therapeutics (NTLA) PT Lowered to $30 at BofA Securities

Oct 27, 2025 09:41AM Intellia Therapeutics Stock Alert: Securities Investigation on Behalf of Intellia Investors - Contact Kehoe Law Firm, P.C. - NTLA

Oct 27, 2025 07:59AM Intellia stock tumbles after pausing gene therapy trials on safety concerns

Oct 27, 2025 07:31AM Intellia pauses gene therapy trials after liver safety event

Oct 6, 2025 02:18AM Citizens Upgrades Intellia Therapeutics (NTLA) to Market Outperform

Sep 19, 2025 06:48AM Intellia Therapeutics (NTLA) PT Raised to $30 at H.C. Wainwright

Sep 19, 2025 04:40AM Citizens JMP Reiterates Market Perform Rating on Intellia Therapeutics (NTLA)

Aug 30, 2025 04:00PM Why public perception matters so much for biotech valuations

View Older Stories